ArticleEmergency medicine journal : EMJ2016
Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
Article in Emergency medicine journal : EMJ, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 102 citations in OpenAlex.
- The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP).The clinical respiratory journal · 2025Trial
- Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management.Therapeutic hypothermia and temperature management · 2024Trial
- Association between variables measured in the ambulance and in-hospital mortality among adult patients with and without infection: a prospective cohort study.BMC emergency medicine · 2022Trial
- Trial
- Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial.Scandinavian journal of trauma, resuscitation and emergency medicine · 2019Trial
- Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy.Disease markers · 2019Trial
- Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III).Scandinavian journal of trauma, resuscitation and emergency medicine · 2018Trial
- Soluble urokinase plasminogen activator receptor - What are the clinical potentials in psychiatry?Brain, behavior, & immunity - health · 2026Review
- PTSD and suPAR: A multicohort investigation of chronic inflammation.Brain, behavior, and immunity · 2026Article
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain.Diagnostics (Basel, Switzerland) · 2025Article
- Enhancing patient stratification methods for medication review during acute admissions.British journal of clinical pharmacology · 2025Article
- SEPSIGN: early identification of sepsis signs in emergency department.Internal and emergency medicine · 2025Observational
- Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation.Journal of arrhythmia · 2025Article
- Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.Cureus · 2024Article
- Examining the association between prenatal and perinatal adversity and the psychotic experiences in childhood.Psychological medicine · 2024Article
- Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood.Brain, behavior, and immunity · 2024Article
- SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes.Brain, behavior, & immunity - health · 2023Article
- Longitudinal links between early adolescent temperament and inflammation among young black adults.Psychoneuroendocrinology · 2023Article
- Challenges facing the clinical adoption of a new prognostic biomarker: a case study.BioSocieties · 2023Article
- Early Life Stress, Neuroinflammation, and Psychiatric Illness of Adulthood.Advances in experimental medicine and biology · 2023Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSoluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker associated with presence and progression of disease and with increased risk of mortality. We aimed to evaluate the unspecific biomarker suPAR as a prognostic marker in patients admitted to acute care.
methodsThis registry-based retrospective cohort study included 4343 consecutively admitted patients from the Acute Medical Unit at a large Danish university hospital. Time to readmission and death were analysed by multiple Cox regression. Results were reported as HRs for 30-day and 90-day follow-up.
resultsDuring 30-day follow-up, 782 patients (18.0%) were readmitted and 224 patients (5.2%) died. Comparing 30-day readmission and mortality between patients in the highest and lowest suPAR quartiles yielded HRs of 2.11 (95% CI 1.70 to 2.62) and 4.11 (95% CI 2.46 to 6.85), respectively, when adjusting for age, sex, Charlson score and C reactive protein. Area under the curve for receiver operating characteristics curve analysis of suPAR for 30-day mortality was 0.84 (95% CI 0.81 to 0.86). Furthermore, in the entire cohort, women had slightly higher suPAR compared with men, and suPAR was associated with age, admission time, admission to intensive care unit and Charlson score.
conclusionsIn this large unselected population of acute medical patients, suPAR is strongly associated with disease severity, readmission and mortality after adjusting for all other risk factors, indicating that suPAR adds information to established prognostic indicators. While patients with low suPAR levels have low risk of readmission and mortality, patients with high suPAR levels have a high risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.